EUCTR2015-005525-39-GB进行中（未招募）1 期
Proof-of-concept study of ibrutinib in c-MYC and HER2 amplified gastrooesophageal carcinoma - iMYC
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Provision of signed and dated, written informed consent prior to any study specific procedures.
- •-Female or male aged 18 years or older.
- •-Histologically proven metastatic or locally advanced inoperable squamous or adeno carcinoma of the oesophagus, stomach or oesophago-gastric junction.
- •-Documented progression after at least 1 prior line of chemotherapy for advanced disease. For HER2 positive tumours documented progression after at least 1 line of chemotherapy with or without HER2 directed therapy.
- •-c-MYC or HER2 gene amplification as defined in trial protocol
- •-Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study. If female patients are taking hormonal contraceptives to prevent pregnancy then this should be combined with a barrier method of contraception. Men must agree to not donate sperm during and after the study. For both males and females restrictions apply for 3 month after the last dose of study drug. See protocol for highly effective methods of birth control.
- •-Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [b-hCG]) or urine pregnancy test at screening. Women who are pregnant or breastfeeding are ineligible for this study.
- •-Mandatory provision of archival or fresh tumour biopsy for confirmation of c-MYC or HER2 gene amplification.
- •-World Health Organisation (ECOG) performance status 0-2, minimum life expectancy of 12 weeks from proposed first dose date, no deterioration within 2 weeks of screening and first dose.
- •-Adequate organ and haematological function as evidenced by the following laboratory values within 14 days before enrolment:
- •absolute neutrophil count (ANC) =1,500/mm3µL
- •platelets =100,000/mm3µL (independent of transfusion support)
- •alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =3 x upper limit of normal (ULN)
- •total bilirubin =1.5 x ULN unless bilirubin rise is due to Gilbert’s syndrome or of non-hepatic origin
- •serum creatinine =2 x ULN or estimated creatinine clearance (CCr) =30 mL/min/1.73m2
- •-At least one measurable target lesion, as per RECIST criteria 1.1
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 17
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 17
排除标准
- •-Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.
- •-Concurrent treatment within 4 weeks of study entry with any other chemotherapy, anticancer immunotherapy or experimental therapy
- •-No available histology for c-MYC or HER-2 amplification testing
- •-Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification
- •-Patients with ECG abrnormalities considered by the investigator to be clinically significant, or repeated baseline prolongation of the rate-corrected QT interval (QTc)
- •-Any actively bleeding gastrooesophageal tumour
- •-History of stroke or intracranial haemorrhage within 6 months prior to enrolment
- •-Symptomatic brain metastases
- •-Known history of human immunodeficiency virus (HIV) or active Hepatitis C Virus or active Hepatitis B Virus infection or any uncontrolled active systemic infection requiring intravenous (IV) antibiotics.
- •-Ongoing anticoagulation with a vitamin K antagonist
- •-Requiring use of strong P450 (CYP) 3A4 inhibitors
- •-Major surgery within 4 weeks of enrolment
- •-Vaccinated with live, attenuated vaccines within 4 weeks of enrolment
- •-Any pre-existing medical condition of sufficient severity to prevent full compliance with the study
研究者
相似试验
Unknown
2 期
Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric CarcinomaGastrooesophageal CancerNCT02884453Royal Marsden NHS Foundation Trust17
进行中（未招募）
1 期
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary TumorsEUCTR2015-003656-40-GBPharmacyclics LLC308
进行中（未招募）
不适用
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary TumorsMetastatic renal cell carcinoma (RCC), advanced urothelial carcinoma, advanced gastric (including gastro-esophageal [GEJ]) adenocarcinoma, and metastatic colorectal adenocarcinoma (CRC)MedDRA version: 18.1Level: PTClassification code 10052360Term: Colorectal adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10050513Term: Metastatic renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: LLTClassification code 10071114Term: Metastatic gastric adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-003656-40-ESPharmacyclics LLC189
进行中（未招募）
1 期
Phase 2 study of ibrutinib plus venetoclax treatment for patients suffering from chronic lymphocytic leukemia / small lymphocytic lymphoma who have never received treatment for this condition previously.EUCTR2016-002293-12-ESPharmacyclics LLC150
已完成
2 期
A Phase II Study of Ibrutinib, Rituximab and mini-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy in very elderly patients with newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)ACTRN12615000551594Australasian Leukaemia and Lymphoma Group80